serviceSupport in the Oncology Area

We answer your research questions and provide insights as a reliable partner with specialized knowledge in the area of oncology.

Cancer is the leading cause of death in Japan. With substantial unmet needs, it is one of the most active fields for pharmaceutical drug development. We offer the support of a team dedicated to oncology research that keeps up with the rapid flow of information and diverse needs of pharmaceutical and medical device manufacturers in this area.

  • icon)

    Clarifying challenges in project

    We work with our clients to clarify challenges in project and research topics to be investigated based on our knowledge and understanding of where the market is headed.

  • icon)

    Providing Actionable Insights

    We not only perform analysis of research results, but also provide post-research support to help clients make strategic decisions and create documents for their internal use based on the research findings.

  • icon)

    Optimizing Research Methods

    We offer optimized research methods based on our understanding of the unique characteristics of the oncology environment in Japan and past trends.


Point 1.

Specialized staff

A team of oncology research specialists who keep up with all the latest trends in oncology by attending a broad range of international and domestic medical congresses, planning and realizing independent events, etc.

<Medical Society Participation> Japanese Gastric Cancer Association, Japanese Breast Cancer Society, The Japan Lung Cancer Society, Japanese Society of Hematology, Japanese Society of Medical Oncology, WCLC, ASCO, ASH, ESMO, etc.

Point 2.

Optimized Proposals

We can conduct research involving a wide range of respondents including clinicians, key opinion leaders (KOLs), pathologists, oncology nurses, oncology pharmacists and patients.
Much experience in a wide range of research methods including online surveys, interviews, home/site visits and mail surveys.

Point 3.

Broad Experience

Over 10 years’ experience in oncology-related research, with over 200 projects per year.

Experienced in a wide variety of cancers such as head and neck, lung, breast, esophageal, gastric, colorectal, hepatic, biliary tract/gall bladder, pancreatic, bladder, prostatic, ovarian, melanoma, soft tissue sarcoma (STS), hematological, unknown primary origin and rare cancers.

Service Outline

Research consultancy in the oncology area

Consultancy project examples:

  • Consultations on the sequence of pre-to-post launch research projects for new anti-cancer drugs entering the market
  • Research to obtain insight from the perspective of pharmacists, nurses, patients and caregivers
  • Physician segmentation proposals based on research data analysis
  • War game/basic sales talks

Other areas of experience include market understanding, patient journeys, purchase process, forecasting, etc.

Disease Data/Fact Book

  • Document collection on various cancers
  • Therapy flow and other information based on diagnostics/test results, classification, medication therapies and guideline of each cancer are available.

* Inquiries on this document collection:

Independent Projects

  • The data obtained by our independent projects have been used by various medical societies.
  • Please inform us if you wish to use our data for any other purpose than personal use.

* Inquiries on independent


  • Research on Genome-based Cancer Treatments (3rd and 4th Surveys)
    • Physicians who diagnose and treat solid tumor cancers
    • Online survey
    • Approximately 1,300 valid completions
    • Half-year research to understand the market and issues of genome-based cancer treatments which commenced in 2019.
  • Research to Understand the Current Usage of and Attitudes toward CAR-T Therapy in Japan, 2nd Survey
    • Hematology
    • Remote interview
    • n=30 valid completions
    • Understand the extent of CAR-T therapy adoption. What issues have been revealed?
  • Research on Genome-based Cancer Treatments (Patients, Families, General Consumers)
    • Cancer patients, families, general Consumers
    • Online survey
    • Approximately 1,600 valid completions
    • It has been one year since genome-based cancer treatment has been approved. What does a genome-based cancer treatment mean for patients, their families and general consumers?
  • Research to Understand the Patient Referral/Acceptance of CAR-T Therapy in Japan
    • Hematology
    • Online survey
    • n=200 valid completions
    • Understand the patient referral of CAR-T Therapy, which is provided only at limited facilities


  • Research to Understand the Current Usage of and Attitude toward CAR-T Therapy in Japan
    • Hematology
    • Office visit interviews
    • n=30 valid completions
    • Research conducted among facilities certified as category 1 or 2 transplant centers by The Japan Society for Hematopoietic Stem Cell Transplantation
  • Research on Genome-based Cancer Treatment (1st and 2nd Survey)
    • Physicians who diagnose and treat solid tumor cancers
    • Online survey
    • Approximately 1,300 valid completions
    • Covered 30 types of cancer and 12 types of genetic tests
  • Research on Immuno-oncology Treatment Access for Non-Small Cell Lung Cancer
    • Physicians who diagnose and treat lung cancer
    • Online survey
    • Approximately 270 valid completions
    • Approximately 750 1st line patient cases
    • Approximately 350 2nd line patient cases


  • Research on Multiple Myeloma (treatment approach by physician type)
    • Hematology
    • Online survey
    • Approximately 200 valid completions
    • Approximately 500 2nd line patient cases
    • Approximately 200 3rd line patient cases
    • RRMM drugs prescribed for various patient types
  • Research on Immuno-oncology Treatment Access and Discontinuation for Non-Small Cell Lung Cancer
    • Physicians who diagnose and treat lung cancer
    • Online survey
    • Approximately 250 valid completions
    • Non-SQ, driver mutation negative patients


  • Research on Hematological Cancer Patient Volume
    • In-depth understanding of patient volume by disease among hematologists

For further information onINTAGE Healthcare Inc.

If you have any questions or comments, please do not hesitate to contact us.

Contact Us



INTAGE Healthcare’s Scope of Service